Loading…

Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial

Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy w...

Full description

Saved in:
Bibliographic Details
Published in:European radiology 1996, Vol.6 (1), p.9-13
Main Authors: Fischbach, R, Landwehr, P, Lackner, K, Nossen, J O, Heindel, W, Berg, K J, Eichhorn, G, Jacobsen, T F
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3
cites cdi_FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3
container_end_page 13
container_issue 1
container_start_page 9
container_title European radiology
container_volume 6
creator Fischbach, R
Landwehr, P
Lackner, K
Nossen, J O
Heindel, W
Berg, K J
Eichhorn, G
Jacobsen, T F
description Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse events were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion of N-acetyl-beta-glucosaminidase (NAG) in the first 24-h collection period after the examination was significantly higher (p < 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.
doi_str_mv 10.1007/BF00619943
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00619943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8797943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMouq5evAs5C9XJppsm3tb1q7DgQT0vk3aKkbYpSVxd8MdbURQGhmEeXngfxk4EnAuA4uLqFkAJY3K5wyYil7NMgM532QSM1FkxPg7YYYyvAGBEXuyzfV2YYsQn7LP0tfvA3rd8E7nzA3auHg_Xj5MCbqj3b5FfPy64b3h6IY629p3rseXoQ0KOfc1b_06B00cK1Lm05RgSBUfxkiOvfDdgwOQ2xIcXjJSVZclTcNgesb0G20jHv3vKnm9vnpb32erhrlwuVlk107OUUTNWsspUoi5Aa5rPtW0U5FaShXkxE5BLhdJY0oYqBcooICVthU2uSVk5ZWc_uVXwMQZq1kNwHYbtWsD62-D63-AIn_7Aw5vtqP5Df5XJL0BDbIY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial</title><source>Springer Online Journals Archive Complete</source><creator>Fischbach, R ; Landwehr, P ; Lackner, K ; Nossen, J O ; Heindel, W ; Berg, K J ; Eichhorn, G ; Jacobsen, T F</creator><creatorcontrib>Fischbach, R ; Landwehr, P ; Lackner, K ; Nossen, J O ; Heindel, W ; Berg, K J ; Eichhorn, G ; Jacobsen, T F</creatorcontrib><description>Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse events were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion of N-acetyl-beta-glucosaminidase (NAG) in the first 24-h collection period after the examination was significantly higher (p &lt; 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.</description><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/BF00619943</identifier><identifier>PMID: 8797943</identifier><language>eng</language><publisher>Germany</publisher><subject>Acetylglucosaminidase - urine ; Adult ; Angiography, Digital Subtraction - adverse effects ; Aorta, Abdominal - diagnostic imaging ; Aortography ; Arteries ; Contrast Media - administration &amp; dosage ; Contrast Media - adverse effects ; Contrast Media - analysis ; Creatinine - blood ; Creatinine - urine ; Double-Blind Method ; Female ; Humans ; Injections, Intravenous ; Iodine - analysis ; Iopamidol - administration &amp; dosage ; Iopamidol - adverse effects ; Iopamidol - analysis ; Kidney - drug effects ; Kidney - enzymology ; Leg - blood supply ; Male ; Middle Aged ; Pain - etiology ; Safety ; Sensation ; Triiodobenzoic Acids - administration &amp; dosage ; Triiodobenzoic Acids - adverse effects ; Triiodobenzoic Acids - analysis</subject><ispartof>European radiology, 1996, Vol.6 (1), p.9-13</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3</citedby><cites>FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8797943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fischbach, R</creatorcontrib><creatorcontrib>Landwehr, P</creatorcontrib><creatorcontrib>Lackner, K</creatorcontrib><creatorcontrib>Nossen, J O</creatorcontrib><creatorcontrib>Heindel, W</creatorcontrib><creatorcontrib>Berg, K J</creatorcontrib><creatorcontrib>Eichhorn, G</creatorcontrib><creatorcontrib>Jacobsen, T F</creatorcontrib><title>Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><description>Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse events were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion of N-acetyl-beta-glucosaminidase (NAG) in the first 24-h collection period after the examination was significantly higher (p &lt; 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.</description><subject>Acetylglucosaminidase - urine</subject><subject>Adult</subject><subject>Angiography, Digital Subtraction - adverse effects</subject><subject>Aorta, Abdominal - diagnostic imaging</subject><subject>Aortography</subject><subject>Arteries</subject><subject>Contrast Media - administration &amp; dosage</subject><subject>Contrast Media - adverse effects</subject><subject>Contrast Media - analysis</subject><subject>Creatinine - blood</subject><subject>Creatinine - urine</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Iodine - analysis</subject><subject>Iopamidol - administration &amp; dosage</subject><subject>Iopamidol - adverse effects</subject><subject>Iopamidol - analysis</subject><subject>Kidney - drug effects</subject><subject>Kidney - enzymology</subject><subject>Leg - blood supply</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain - etiology</subject><subject>Safety</subject><subject>Sensation</subject><subject>Triiodobenzoic Acids - administration &amp; dosage</subject><subject>Triiodobenzoic Acids - adverse effects</subject><subject>Triiodobenzoic Acids - analysis</subject><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LxDAQhoMouq5evAs5C9XJppsm3tb1q7DgQT0vk3aKkbYpSVxd8MdbURQGhmEeXngfxk4EnAuA4uLqFkAJY3K5wyYil7NMgM532QSM1FkxPg7YYYyvAGBEXuyzfV2YYsQn7LP0tfvA3rd8E7nzA3auHg_Xj5MCbqj3b5FfPy64b3h6IY629p3rseXoQ0KOfc1b_06B00cK1Lm05RgSBUfxkiOvfDdgwOQ2xIcXjJSVZclTcNgesb0G20jHv3vKnm9vnpb32erhrlwuVlk107OUUTNWsspUoi5Aa5rPtW0U5FaShXkxE5BLhdJY0oYqBcooICVthU2uSVk5ZWc_uVXwMQZq1kNwHYbtWsD62-D63-AIn_7Aw5vtqP5Df5XJL0BDbIY</recordid><startdate>1996</startdate><enddate>1996</enddate><creator>Fischbach, R</creator><creator>Landwehr, P</creator><creator>Lackner, K</creator><creator>Nossen, J O</creator><creator>Heindel, W</creator><creator>Berg, K J</creator><creator>Eichhorn, G</creator><creator>Jacobsen, T F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1996</creationdate><title>Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial</title><author>Fischbach, R ; Landwehr, P ; Lackner, K ; Nossen, J O ; Heindel, W ; Berg, K J ; Eichhorn, G ; Jacobsen, T F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Acetylglucosaminidase - urine</topic><topic>Adult</topic><topic>Angiography, Digital Subtraction - adverse effects</topic><topic>Aorta, Abdominal - diagnostic imaging</topic><topic>Aortography</topic><topic>Arteries</topic><topic>Contrast Media - administration &amp; dosage</topic><topic>Contrast Media - adverse effects</topic><topic>Contrast Media - analysis</topic><topic>Creatinine - blood</topic><topic>Creatinine - urine</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Iodine - analysis</topic><topic>Iopamidol - administration &amp; dosage</topic><topic>Iopamidol - adverse effects</topic><topic>Iopamidol - analysis</topic><topic>Kidney - drug effects</topic><topic>Kidney - enzymology</topic><topic>Leg - blood supply</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain - etiology</topic><topic>Safety</topic><topic>Sensation</topic><topic>Triiodobenzoic Acids - administration &amp; dosage</topic><topic>Triiodobenzoic Acids - adverse effects</topic><topic>Triiodobenzoic Acids - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fischbach, R</creatorcontrib><creatorcontrib>Landwehr, P</creatorcontrib><creatorcontrib>Lackner, K</creatorcontrib><creatorcontrib>Nossen, J O</creatorcontrib><creatorcontrib>Heindel, W</creatorcontrib><creatorcontrib>Berg, K J</creatorcontrib><creatorcontrib>Eichhorn, G</creatorcontrib><creatorcontrib>Jacobsen, T F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fischbach, R</au><au>Landwehr, P</au><au>Lackner, K</au><au>Nossen, J O</au><au>Heindel, W</au><au>Berg, K J</au><au>Eichhorn, G</au><au>Jacobsen, T F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial</atitle><jtitle>European radiology</jtitle><addtitle>Eur Radiol</addtitle><date>1996</date><risdate>1996</risdate><volume>6</volume><issue>1</issue><spage>9</spage><epage>13</epage><pages>9-13</pages><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Iodixanol (Visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mgI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse events were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion of N-acetyl-beta-glucosaminidase (NAG) in the first 24-h collection period after the examination was significantly higher (p &lt; 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.</abstract><cop>Germany</cop><pmid>8797943</pmid><doi>10.1007/BF00619943</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0938-7994
ispartof European radiology, 1996, Vol.6 (1), p.9-13
issn 0938-7994
1432-1084
language eng
recordid cdi_crossref_primary_10_1007_BF00619943
source Springer Online Journals Archive Complete
subjects Acetylglucosaminidase - urine
Adult
Angiography, Digital Subtraction - adverse effects
Aorta, Abdominal - diagnostic imaging
Aortography
Arteries
Contrast Media - administration & dosage
Contrast Media - adverse effects
Contrast Media - analysis
Creatinine - blood
Creatinine - urine
Double-Blind Method
Female
Humans
Injections, Intravenous
Iodine - analysis
Iopamidol - administration & dosage
Iopamidol - adverse effects
Iopamidol - analysis
Kidney - drug effects
Kidney - enzymology
Leg - blood supply
Male
Middle Aged
Pain - etiology
Safety
Sensation
Triiodobenzoic Acids - administration & dosage
Triiodobenzoic Acids - adverse effects
Triiodobenzoic Acids - analysis
title Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A22%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Iodixanol%20vs%20iopamidol%20in%20intravenous%20DSA%20of%20the%20abdominal%20aorta%20and%20lower%20extremity%20arteries:%20a%20comparative%20phase-III%20trial&rft.jtitle=European%20radiology&rft.au=Fischbach,%20R&rft.date=1996&rft.volume=6&rft.issue=1&rft.spage=9&rft.epage=13&rft.pages=9-13&rft.issn=0938-7994&rft.eissn=1432-1084&rft_id=info:doi/10.1007/BF00619943&rft_dat=%3Cpubmed_cross%3E8797943%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c282t-ef432b69c1d7088e558bf604b3eb057210436a39be89ec606960e63bcaf48e6b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/8797943&rfr_iscdi=true